<DOC>
	<DOCNO>NCT01485861</DOCNO>
	<brief_summary>This multicenter , international , Phase Ib/II trial consist two stage : Phase Ib , open-label stage recommend Phase II dose determine ipatasertib GDC-0980 combination abiraterone prednisone/prednisolone Phase II , 3-arm , double-blind , randomized comparison ipatasertib abiraterone prednisone/prednisolone versus placebo abiraterone prednisone/prednisolone .</brief_summary>
	<brief_title>Study Ipatasertib GDC-0980 With Abiraterone Acetate Versus Coralie Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Histologically confirm metastatic advanced prostate adenocarcinoma previously treat docetaxel progress treatment least one hormonal therapy Two rise PSA level great equal ( &gt; /= ) 2 ng/mL measure &gt; /= 1 week apart radiographic evidence disease progression soft tissue bone Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 screen Adequate hematologic organ function Documented willingness use effective mean contraception History Type I Type II diabetes mellitus require insulin New York Heart Association Class III IV heart failure Left ventricular ejection fraction &lt; 50 % ventricular arrhythmia require medication Significant atherosclerotic disease , evidence : unstable angina , history myocardial infarction within 6 month prior Day 1 , cerebrovascular accident within 6 month prior Day 1 Active autoimmune disease control nonsteroidal antiinflammatory drug active inflammatory disease require immunosuppressive therapy Clinically significant history liver disease History adrenal insufficiency hyperaldosteronism Phase II : Previous therapy prostate cancer 17 alphahydroxylase/C17,20lyase inhibitor , include abiraterone Phase II : Previous treatment prostate cancer Protein kinase B phosphatidylinositol 3 kinase and/or mammalian target rapamycin inhibitor Need chronic corticosteroid therapy &gt; /= 20 mg prednisone per day equivalent dose anti inflammatory corticosteroid immunosuppressant</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>